

Application No. 09/647,981  
Amdt. dated May 13, 2005  
Reply to Office Action of 11/17/04

2

Amendments to the Claims:

1. (Currently amended) A method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host, which comprises:  
  
administering to the host a T-helper molecule to prime T-helper cells of the immune system of the host, and  
  
subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host, said T-cell inducing HIV-derived molecule being a peptide corresponding to a portion of an HIV-1 antigen and containing at least one T-cell epitope.
2. (Original) The method of claim 1 wherein said T-helper molecule is selected from HLA class II restricted T-helper epitopes.
3. (Original) The method of claim 2 wherein said T-helper epitopes are selected from the group consisting of DP, DR and DQ-specific T-cell epitopes.
4. (Original) The method of claim 2 wherein said T-helper molecule is CLP-243 (SEQ ID NO:10).
5. (Original) The method of claim 1 wherein said T-helper molecule is administered with an adjuvant.
6. (Cancelled)
7. (Currently amended) The method of claim 1 ~~claim 5~~ wherein said peptide corresponds ~~correspond~~ to sequences of the Rev protein of HIV-1.
8. (Currently amended) The method of claim 1 ~~claim 6~~ wherein said peptide is a lipopeptide.
9. (Original) The method of claim 8 wherein the lipid is palmitoyl or cholesterol.

Application No. 09/647,981  
Amdt. dated May 13, 2005  
Reply to Office Action of 11/17/04

3

10. (Original) The method of claim 7 wherein said lipopeptide is CLP-175 or CLP-176.

11. (Currently amended) The method of claim 1 ~~claim 6~~ wherein said mixture is administered with an adjuvant.

12. to 15. (Cancelled)